LANRAPLENIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H25N9O
Molecular Weight	443.5043
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=CN=CC(=N1)C2=CN3C=CN=C3C(NC4=CC=C(C=C4)N5CCN(CC5)C6COC6)=N2

InChI

InChIKey=XCIGZBVOUQVIPI-UHFFFAOYSA-N

InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)

HIDE SMILES / InChI

Molecular Formula	C23H25N9O
Molecular Weight	443.5043
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

C_max

Value	Dose	Analyte	Population
134.4 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
131.6 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
118 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2478.7 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2153 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2223.4 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32292557/			LANRAPLENIB plasma	Homo sapiens

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:52:30 GMT 2025` Edited by `admin` on `Wed Apr 02 09:52:30 GMT 2025`
Record UNII	A6U64OU57E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LANRAPLENIB

Official Name

English

GS-SYK

Preferred Name

English

6-(6-AMINO-2-PYRAZINYL)-N-(4-(4-(3-OXETANYL)-1-PIPERAZINYL)PHENYL)IMIDAZO(1,2-A)PYRAZIN-8-AMINE

Systematic Name

English

IMIDAZO(1,2-A)PYRAZIN-8-AMINE, 6-(6-AMINO-2-PYRAZINYL)-N-(4-(4-(3-OXETANYL)-1-PIPERAZINYL)PHENYL)-

Systematic Name

English

LANRAPLENIB [USAN]

Common Name

English

6-(6-Aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine

Systematic Name

English

lanraplenib [INN]

Common Name

English

Lanraplenib [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

A6U64OU57E